Latest Manufacturing Processes News

Page 2 of 14
Actinogen Medical has locked in full underwriting for nearly 127 million unlisted options, guaranteeing $4.77 million in fresh funding as it approaches pivotal Alzheimer’s trial results due in November.
Ada Torres
Ada Torres
1 Sept 2026
Advance ZincTek posted an 11% rise in FY26 profit before tax to $2.247 million on 12.6% higher sales, driven by AI integration and US market strength. The company is set to enter residential battery manufacturing in FY27, leveraging its zinc oxide expertise.
Maxwell Dee
Maxwell Dee
31 Aug 2026
Actinogen Medical reported a $15.38 million loss for FY2026 while progressing its lead Alzheimer's drug Xanamem toward pivotal trial results expected this November. The company secured regulatory alignment and strengthened its cash position to fund operations through mid-2027.
Ada Torres
Ada Torres
27 Aug 2026
Clinuvel Pharmaceuticals marked its tenth consecutive profit with stable revenues and rising cash reserves, while accelerating U.S. expansion including a Nasdaq uplisting and potential ASX delisting.
Victor Sage
Victor Sage
27 Aug 2026
NeuroScientific Biopharmaceuticals posted a $4.69 million loss for FY2026, driven by R&D ramp-up and clinical progress with its StemSmart™ platform, while halting independent development of its glaucoma drug EmtinB to pursue licensing deals.
Ada Torres
Ada Torres
25 Aug 2026
HighCom Limited’s FY26 results reveal a sharp revenue drop and widening loss driven by a US Government shutdown, but a strengthened leadership team and expanded global sales pipeline set the stage for recovery.
Victor Sage
Victor Sage
25 Aug 2026
Entropy Neurodynamics has partnered with BioCina to establish GMP manufacturing for its intravenous psilocin formulation TRP-8803, a critical step toward late-stage clinical trials and commercialisation.
Ada Torres
Ada Torres
19 Aug 2026
Barramundi Limited’s portfolio delivered a 2.2% gross return in July, outpacing the S&P/ASX200 hedged benchmark, driven by strong performances in healthcare and financials alongside strategic portfolio adjustments.
Claire Turing
Claire Turing
17 Aug 2026
NeuroScientific Biopharmaceuticals (ASX:NSB) has locked in a key FDA Pre-IND meeting for late August, advancing its Phase 2 trial plans for StemSmart™ targeting refractory Crohn’s disease in the US and Australia.
Ada Torres
Ada Torres
13 Aug 2026
EBR Systems marked a commercial milestone with over 100 WiSE CRT implants and secured purchasing agreements with three major US healthcare networks. The company is progressing toward Medicare coverage and scaling manufacturing, supported by a near-complete A$150 million capital raise.
Ada Torres
Ada Torres
12 Aug 2026
Actinogen Medical’s pivotal XanaMIA Alzheimer’s trial stays on track for November topline results, buoyed by strong open-label extension enrolment and aligned EMA-FDA regulatory advice. A new antidepressant study publication and fresh patents add momentum, supported by a $16.7 million cash runway to mid-2027.
Ada Torres
Ada Torres
30 July 2026
AdAlta has completed a key US$1 million milestone payment securing rights to its lead CAR-T therapy EW-001 outside Greater China, progressed Australian manufacturing with first runs expected late 2026, and is preparing for a critical pre-IND meeting with the US FDA.
Ada Torres
Ada Torres
29 July 2026

Browse the archive

Full archive